NCT02368314View on ClinicalTrials.gov

A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries

PHASE3CompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Deep Vein Thrombosis

Interventions

DRUG

Sodium Enoxaparine

30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).

Trial Locations (1)

Unknown

Railroad Clinical Hospital at the station Chelyabinsk, Chelyabinsk

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biocad

INDUSTRY